Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.

Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.

Abstract: A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.

Abstract: An antibody that binds to HER2 expressed on a cancer cell or a fragment of the HER2, or an antigen binding fragment thereof are disclosed. Uses of the antibody or antigen binding fragment thereof are disclosed. The antibody or antigen binding fragment thereof is useful to target a HER2 expressing cancer cells. A-pharmaceutical composition containing the antibody or antigen binding fragment thereof is also disclosed.

Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Abstract: The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.

Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.

Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

Abstract: A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof.

Abstract: A suppression of postsurgical recurrence and/or metastasis of cancer by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery is disclosed. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, containing a beta-blocker and being administered during a perioperative period of cancer surgery.

Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.

Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Abstract: New uses of an FF-MAS metabolism inhibitor for protecting and/or regenerating a neuromuscular junction or for treating and/or preventing a disorder of a neuromuscular junction are disclosed. In one aspect, a method for protecting and/or regenerating a neuromuscular junction or a method for treating and/or preventing a disorder of a neuromuscular junction, the method including administering an effective amount of an FF-MAS metabolism inhibitor to a mammal is disclosed. In one aspect, an FF-MAS metabolism inhibitor for use in protecting and/or regenerating a neuromuscular junction or for use in treating and/or preventing a disorder of a neuromuscular junction is disclosed. In one aspect, uses of an FF-MAS metabolism inhibitor for manufacturing an agent for protecting and/or regenerating a neuromuscular junction or for manufacturing an agent for treating and/or preventing a disorder of a neuromuscular junction are disclosed.

Abstract: The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient. As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1) [in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed. Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

Abstract: A method for removing coloration from a drug substance solution of protein preparation, in particular, antibody preparation, a method for preparing drug substance solution of protein preparations including it, as a part thereof, and highly concentrated, colorless drug substance solutions thereof are disclosed. The method removes terminal glycation products causing the coloration in the drug substance solution of protein preparation, in particular, antibody preparation, by anion-exchange chromatography, making it possible to provide colorless drug substance solutions.